ライフサイエンスコーパス: irinotecan

1 toxicity of, SN38 (the active metabolite of irinotecan).

2 L patients, most commonly fluoropyrimidine + irinotecan.

3 delivery of SN-38, the active metabolite of irinotecan.

4 osis, and were refractory to oxaliplatin and irinotecan.

5 combinatorial treatment of Pitavastatin and Irinotecan.

6 ther cetuximab monotherapy or cetuximab plus irinotecan.

7 8-a prodrug of the topoisomerase I inhibitor irinotecan.

8 gs and the same cytotoxicity as unformulated irinotecan.

9 city and maintains the antitumor efficacy of irinotecan.

10 isting of a platinum agent plus etoposide or irinotecan.

11 nsitivity to SN-38, the active metabolite of irinotecan.

12 s active metabolite SN-38 compared with free irinotecan.

13 otype can be used to individualize dosing of irinotecan.

14 n PFS between treatment arms with or without irinotecan.

15 imination of SN-38, the active metabolite of irinotecan.

16 ded dosing on efficacy in patients receiving irinotecan.

17 droxycamptothecin), the active metabolite of irinotecan.

18 ess the distribution of the anticancer drug, irinotecan.

19 FL118 shows structural similarity to irinotecan.

20 rs as a single agent and in combination with irinotecan.

21 stemic chemotherapy including oxaliplatin or irinotecan.

22 inhibition alters the anticancer efficacy of irinotecan.

23 roved topoisomerase inhibitors topotecan and irinotecan.

24 camptothecin anticancer drugs topotecan and irinotecan.

25 rontline colorectal cancer chemotherapy drug irinotecan.

26 tic index of SN-38, the active metabolite of irinotecan.

27 luding a fluoropyrimidine and oxaliplatin or irinotecan.

28 The first group was given irinotecan (100 mg/kg), the second oxaliplatin (5 mg/kg)

29 received adjuvant oxaliplatin could receive irinotecan 180 mg/m(2) intravenously over 30 min with fl

30 en 250 mg/m(2) once per week with or without irinotecan 180 mg/m(2) once every 2 weeks.

31 er FOLFIRINOX alone (oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), and bolu

32 receive FOLFIRINOX (oxaliplatin, 85 mg/m(2); irinotecan, 180 mg/m(2); leucovorin, 400 mg/m(2); and fl

33 /m(2) per day intravenously on days 1 and 8; irinotecan, 20 mg/m(2) per day intravenously on days 1-5

34 h fluorouracil (77.1% vs 46.6%, p=0.037) and irinotecan (41.7% vs 24.4%, p=0.006).

35 80 mg/m(2) per day on days 1 to 7 along with irinotecan 50 mg/m(2) intravenously and temozolomide 100

36 Irinotecan 50 mg/m(2)/day for 5 days was the MTD when co

37 omide (100 mg/m(2) per dose) and intravenous irinotecan (50 mg/m(2) per dose) on days 1-5 of 21-day c

38 the second oxaliplatin (5 mg/kg), the third irinotecan (80 mg/kg) plus oxaliplatin (5 mg/kg), and th

39 A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irin

40 with distinct circadian toxicity patterns of irinotecan, a topoisomerase I inhibitor active against c

41 e cell viability was never below 80% whereas irinotecan achieved cell viabilities of less than 44%.

42 ients with disease known to be responsive to irinotecan achieved partial response.

43 administered at doses 5-fold lower than free irinotecan achieved similar intratumoral exposure of SN-

44 either AZD2014 or INK128 in combination with irinotecan, acted synergistically to induce apoptosis bo

45 se (MTD) and dose limiting toxicity (DLT) of irinotecan administered in combination with vincristine,

46 Irinotecan administration caused significant delay in th

47 can against HT-29 cells and was as potent as irinotecan against A549 cells in xenograft models.

48 ealed that compound 18a was more potent than irinotecan against HT-29 cells and was as potent as irin

49 We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folin

50 n with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P < .00

51 ing tumors to a fraction of that achieved by irinotecan alone, while simultaneously promoting epithel

52 ions of FUS, FUS and 10 mg/kg irinotecan, or irinotecan alone.

53 230 patients were randomly allocated to irinotecan and 230 to IrPan.

54 hese lines were tested for their response to irinotecan and a Chk1 inhibitor (either UCN-01 or AZD776

55 ow evidence of drug-drug interaction between irinotecan and alisertib.

56 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infe

57 IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]).

58 phase II trial evaluating the combination of irinotecan and cetuximab every second week, as third-lin

59 ne or two regimens were randomly assigned to irinotecan and cetuximab with or without vemurafenib (96

60 nd 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively.

61 versus a non-platinum-containing regimen of irinotecan and docetaxel (IT) differed according to ERCC

62 ve higher intratumoral levels of the prodrug irinotecan and its active metabolite SN-38 compared with

63 trexate, doxorubicin, paclitaxel, docetaxel, irinotecan and its important metabolite 7-ethyl-10-hydro

64 cted the abundance change of anticancer drug irinotecan and its metabolites inside spheroids treated

65 lism of xenobiotics, including drugs such as irinotecan and oseltamivir.

66 isease, modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) is the standard

67 results suggest that nanomedicine mimicking irinotecan and oxaliplatin as parts of FOLFIRINOX regime

68 FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally adv

69 polymeric micelles bearing active formats of irinotecan and oxaliplatin, SN38 and 1,2-diaminocyclohex

70 in conjugation by 70% and is associated with irinotecan and protease inhibitor side effects.

71 dose for 7 days is tolerable with a standard irinotecan and temozolomide backbone and has promising r

72 The combination of irinotecan and temozolomide has activity in these patien

73 Irinotecan and temozolomide have activity in patients wi

74 ximum tolerated dose (MTD) of alisertib with irinotecan and temozolomide in this population.

75 as used to randomly assign patients (1:1) to irinotecan and temozolomide plus either temsirolimus or

76 h a combination of the chemotherapeutic drug irinotecan and the monoclonal antibody cetuximab.

77 o other FDA-approved camptothecin analogues (irinotecan and topotecan).

78 he cancer chemotherapeutics derived from it, irinotecan and topotecan, are highly specific inhibitors

79 All patients had irinotecan and/or oxaliplatin-based chemotherapy before

80 y of 5c with SN-38 (the active metabolite of irinotecan) and 5-fluorouracil on cell proliferation und

81 tween FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epirubicin, cisplatin,and capecitab

82 For the anticancer drug CPT-11 (irinotecan) and the nonsteroidal anti-inflammatory drug

83 The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients wi

84 a randomized clinical trial of panitumumab, irinotecan, and ciclosporin in colorectal cancer (PICCOL

85 therapy (comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients with metastati

86 litaxel, oxaliplatin, rituximab, infliximab, irinotecan, and other drugs).

87 of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), restrict their

88 eiving induction 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).

89 PH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated

90 tatic setting (eg, fluorouracil, leucovorin, irinotecan, and oxaliplatin and gemcitabine plus nanopar

91 mbinations such as fluorouracil, leucovorin, irinotecan, and oxaliplatin as well as gemcitabine/nab-p

92 (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nab-pa

93 OX (fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nanopa

94 (combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) offers survival benefits su

95 argets, and interaction with 5-fluorouracil, irinotecan, and oxaliplatin.

96 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin; favorable comorbidity profi

97 e combination of a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete respons

98 ptothecin and its derivatives, topotecan and irinotecan, are specific topoisomerase I (Top1) inhibito

99 mined in phase II window studies, and use of irinotecan as a radiation sensitizer.

100 oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC.

101 in at 65 mg/m(2), leucovorin at 400 mg/m(2), irinotecan at 140 mg/m(2), and fluorouracil 400 mg/m(2)

102 ntinuously days 1 through 35 and intravenous irinotecan at 60 mg/m(2) once weekly weeks 1 to 4.

103 lus bevacizumab, followed by the addition of irinotecan at first progression (arm A) versus upfront u

104 urve (AUCs; r(2) = 0.0003; P = .97), but the irinotecan AUC was correlated with the actual dose (r(2)

105 every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid.

106 can (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid ever

107 antage of bevacizumab was more apparent with irinotecan-based chemotherapy (HR, 0.80; 95% CI, 0.66 to

108 re aggressive intervention (oxaliplatin- and irinotecan-based chemotherapy and/or surgery for recurre

109 ed to be candidates for oxaliplatin-based or irinotecan-based chemotherapy regimens, were randomly as

110 h mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment

111 and 2011 and treated with oxaliplatin and/or irinotecan-based preoperative chemotherapy were eligible

112 GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ.

113 management of treatment with bevacizumab and irinotecan (BEV/IR) in patients with recurrent high-grad

114 The demonstrated efficacy of adding irinotecan, bevacizumab, or cetuximab to fluorouracil-ba

115 ur work shows how liposomal encapsulation of irinotecan can safely improve its antitumor activity in

116 The ICECREAM (Irinotecan Cetuximab Evaluation and Cetuximab Response E

117 S) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma mo

118 -erbalpha and Bmal1 mRNA expressions and for irinotecan chronotoxicity in clock-altered Per2(m/m) mic

119 Irinotecan clearance followed linear kinetics.

120 ant KRAS tumors indicated that the anti-DLL4/irinotecan combination produced a significant decrease i

121 ties for the clinical translation of PDT and irinotecan combination therapy for effective pancreatic

122 erval, pretreatment with an 80 mg/kg dose of irinotecan combined with 2 fractions of 4.5 Gy in a 24-h

123 Irinotecan concentrations in the brain were significantl

124 ds Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govit

125 re recruited to a three-arm design including irinotecan (control), irinotecan plus ciclosporin, and i

126 Here, we prepared PEG conjugates of the irinotecan (CPT-11) active metabolite SN-38 via a phenyl

127 m are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affinity.

128 ability of SN22 vs. SN38 (the active form of irinotecan/CPT-11) to overcome efflux pump-driven drug r

129 While irinotecan delivery to the brain was not neurotoxic, it

130 Adding panitumumab to irinotecan did not improve the overall survival of patie

131 0% of the samples and only with an excessive irinotecan dose.

132 g a hot melt extrusion process with accurate irinotecan drug loadings and the same cytotoxicity as un

133 ing cassette G2 (ABCG2) transporter-mediated irinotecan efflux from cells.

134 Drugs such as gemcitabine and irinotecan elicit their therapeutic effect in cancer cel

135 These drugs included topotecan, irinotecan, etoposide and dexrazoxane (ICRF-187).

136 both groups received 350 mg/m(2) intravenous irinotecan every 3 weeks (300 mg/m(2) if aged >/=70 year

137 as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and ox

138 ith first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Com

139 ith first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Com

140 combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line t

141 f cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall surv

142 compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI).

143 fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, contr

144 l fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets

145 h fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) showed superior efficacy as compa

146 r sensitivity to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX (5-FU+oxaliplati

147 -line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients

148 tudy design included two dose levels (DL) of irinotecan given intravenously once daily for 5 consecut

149 ths, two in the IrPan group and three in the irinotecan group.

150 [12%]; p<0.0001) than did individuals in the irinotecan group.

151 more commonly in the IrPan group than in the irinotecan group.

152 ns continued on standard-dose cetuximab plus irinotecan (group C).

153 Irinotecan had a 75% response rate, while only 50% respo

154 Camptothecin (CPT)-11 (irinotecan) has been used widely for cancer treatment, p

155 Both Irinotecan/HAS2 (Hyaluronan synthase 2) and Bevacizumab/

156 n with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P = .73; inte

157 tment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calciu

158 toperative leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) v

159 identified a patient prescribed a regimen of irinotecan hydrochloride, cetuximab, and ramucirumab for

160 is of new liver and lung metastases in 2010, irinotecan in 2011, and then cetuximab until progression

161 The iDES released irinotecan in a sustained fashion for up to 7 days.

162 mass spectrometry (LC/MS) quantifications of irinotecan in cell lysate samples were used to compare t

163 Nanoliposomal irinotecan in combination with fluorouracil and folinic

164 lus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorect

165 lus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorect

166 olute quantifications of the anticancer drug irinotecan in individual mammalian cancer cells under am

167 se (MTD) and dose-limiting toxicity (DLT) of irinotecan in patients with advanced solid tumors strati

168 ess cetuximab monotherapy and cetuximab plus irinotecan in patients with molecularly selected (G13D m

169 was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer.

170 e the cytotoxicity of the DNA damaging agent irinotecan in TNBC using xenotransplant tumor models.

171 , FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) in a 3D printed fluidic device.

172 0203, FOLFIRI (fluorouracil, leucovorin, and irinotecan) in study 20050181, or best supportive care i

173 esistance to SN-38, the active metabolite of irinotecan, in LS174T cells.

174 irmed by encapsulating a cancer therapeutic, irinotecan, in the compartment containing the acetal-mod

175 We demonstrate that a single dose of irinotecan increases GI bacterial GUS activity in 1 d an

176 hibitor also effectively blocks the striking irinotecan-induced bloom of Enterobacteriaceae in immune

177 itors have been shown to partially alleviate irinotecan-induced GI tract damage and resultant diarrhe

178 nd IL-18, which mediate tissue injury during irinotecan-induced mucositis in mice.

179 s and the role of inflammasome activation in irinotecan-induced mucositis.

180 ole of glucuronidation in protecting against irinotecan-induced toxicity.

181 Mucositis in mice was induced by irinotecan injection in C57BL/6 wild-type, gp91phox(-/-)

182 ferences in PK parameters was the lowest for irinotecan, intermediate for oxaliplatin and the largest

183 ion, indicating that 5-fluorouracil (5-FU) + irinotecan (IRI) + bevacizumab (BEV) and regorafenib (RE

184 Both doxorubicin (Dox) and irinotecan (Iri) elution kinetics for all bead sizes eva

185 otherapy either alone or in combination with irinotecan (IRI) in the Federation Francophone de Cancer

186 n chemotherapeutic drugs, gemcitabine (GEM), irinotecan (IRIN), and a prodrug form of 5-flurouracil (

187 Irinotecan is a useful chemotherapeutic for the treatmen

188 Nanoliposomal irinotecan is approved by the FDA for gemcitabine-refrac

189 us inhibition of EGFR and BRAF combined with irinotecan is effective in BRAF(V600E)-mutated CRC.

190 m recurrent GBM patients to demonstrate that irinotecan is more effective than temozolomide.

191 sk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant th

192 Irinotecan is used clinically for the treatment of color

193 Irinotecan is used for colorectal cancer treatment but t

194 ct, and it was increased in combination with irinotecan, leading to tumor regression and replacement

195 leucovorin, and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line

196 d ABCG2 expression to increase intracellular irinotecan levels in pancreatic cancer.

197 Phage-guided irinotecan-loaded dextran nanoparticles promote release

198 es the development of a novel formulation of Irinotecan-loaded Drug Eluting Seeds (iDES) for insertio

199 nfusion via a hepatic arterial pump or port, irinotecan-loaded drug-eluting beads, and radioembolizat

200 In this issue of the JCI, Liu et al. use irinotecan-loaded nanoparticles to treat pancreatic aden

201 nistration of iRGD enhanced the uptake of an irinotecan-loaded silicasome carrier that comprises lipi

202 monstrate that iRGD enhances the efficacy of irinotecan-loaded silicasome-based therapy and may be a

203 served with the combination of cetuximab and irinotecan may reflect true drug synergy or persistent i

204 ral location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equiv

205 acil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and foli

206 ffer between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil

207 Irinotecan monotherapy was common in Australia (30.0% of

208 tic cancer, combining PDP with nanoliposomal irinotecan (nal-IRI) prevented tumor relapse, reduced me

209 r activity of a nanoliposomal formulation of irinotecan (nal-IRI).

210 formulations released the 300 to 1000 mug of irinotecan needed to be effective in vivo.

211 In mechanistic studies, irinotecan not only induces apoptosis by eliciting a DNA

212 nse) to randomly allocate patients to either irinotecan or IrPan.

213 A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a

214 ased chemoresistance to fluorouracil but not irinotecan or oxaliplatin.

215 he introduction of nanocarriers that deliver irinotecan or paclitaxel.

216 itabine and/or bevacizumab, cetuximab and/or irinotecan, or erlotinib resulted in increased antitumor

217 ree weekly sessions of FUS, FUS and 10 mg/kg irinotecan, or irinotecan alone.

218 dity profile; fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal irinotecan should be offere

219 were treated with either the cytotoxic drug, Irinotecan, or saline as control.

220 rectal radiotherapy, and the use of combined irinotecan/oxaliplatin chemotherapy were more frequent i

221 nitial dose, then 250 mg/m(2) per week) plus irinotecan, patients with </= grade 1 skin reactions wer

222 versus upfront use of fluoropyrimidine plus irinotecan plus bevacizumab (arm B) in a 1:1 randomized,

223 ombination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an establ

224 e-arm design including irinotecan (control), irinotecan plus ciclosporin, and irinotecan plus panitum

225 and continuous-infusion fluorouracil (ECF), irinotecan plus cisplatin (IC), or FOLFOX (oxaliplatin,

226 were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), n

227 survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 mo

228 y in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutr

229 ith FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil).

230 incidence of early nausea for patients given irinotecan plus oxaliplatin (IROX) compared with those g

231 had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bol

232 (control), irinotecan plus ciclosporin, and irinotecan plus panitumumab (IrPan) groups.

233 f the bioengineered ASCs in combination with irinotecan prodrug in the designed sequence and timeline

234 toneal dosing of the clinically used prodrug irinotecan produces high initial and local concentration

235 followed by later treatment with taxanes and irinotecan, provides some benefit.

236 inotecan treatment, we also demonstrate that irinotecan reduced the tumoral expression of monocarboxy

237 f cetuximab dose escalation in patients with irinotecan-refractory metastatic colorectal cancer who h

238 the mechanisms of cancer cell resistance to irinotecan remains poorly understood.

239 identify perturbed chromatin acetylation in irinotecan resistance and establish HDAC inhibitors as p

240 ated colorectal cancer (CRC) cell models for irinotecan resistance and report that resistance is neit

241 Selection of irinotecan resistance in colon carcinoma cells led to a

242 Subsequent treatment of irinotecan-resistant, but not parental, CRC cells with h

243 tter two could be employed following loss of irinotecan response.

244 se intensification, it dramatically improves irinotecan's effectiveness, reducing tumors to a fractio

245 Interestingly, irinotecan selectively inhibited hOCT1, whereas crizotin

246 may reflect true drug synergy or persistent irinotecan sensitivity.

247 us oxaliplatin, irinotecan, or nanoliposomal irinotecan should be offered to patients with first-line

248 Nanoliposomal irinotecan showed activity in a phase 2 study in patient

249 tibody, conjugated with active metabolite of irinotecan (SN-38), on Trop-2 positive cervical cancer c

250 FL118 was no better than the active form of irinotecan, SN-38 at 1 microM, FL118 effectively inhibit

251 PDT and a subclinical dose of nanoliposomal irinotecan synergistically inhibited tumor growth by 70%

252 The combination of irinotecan, temozolomide, dintuximab, and granulocyte-ma

253 e addition of temsirolimus or dinutuximab to irinotecan-temozolomide in patients with relapsed or ref

254 INTERPRETATION: Irinotecan-temozolomide-dinutuximab met protocol-defined

255 Irinotecan-temozolomide-dinutuximab shows notable anti-t

256 Of the 17 patients assigned to irinotecan-temozolomide-dinutuximab, nine (53%; 95% CI 2

257 inotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-dinutuximab.

258 ng 35 patients, 18 were randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinoteca

259 e combination meriting further study whereas irinotecan-temozolomide-temsirolimus did not.

260 Of the 18 patients assigned to irinotecan-temozolomide-temsirolimus, one patient (6%; 9

261 Among these, the irinotecan/temozolomide combination induced strong tumor

262 anthracycline, 4 cisplatin, 1 paclitaxel, 1 irinotecan) that meet inclusion criteria, with a total o

263 which tested the addition of panitumumab to irinotecan therapy in patients with KRAS wt aCRC who exp

264 e mCRC who had progressed within 6 months of irinotecan therapy were randomly assigned to cetuximab 4

265 metastatic colorectal cancer, all with prior irinotecan therapy.

266 ssions that accurately predicted for optimal irinotecan timing.

267 hances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastati

268 ownregulation of the main cellular target of irinotecan TOP1 nor upregulation of the key TOP1 PDB rep

269 an tumor xenograft models in comparison with irinotecan, topotecan, doxorubicin, 5-FU, gemcitabine, d

270 Moreover, we found that irinotecan treatment dramatically altered the compositio

271 Irinotecan treatment is associated with mucositis, which

272 However, the full potential of irinotecan treatment is hindered by several cancer cell

273 Irinotecan treatment resulted in increased IL-1beta and

274 The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1

275 ere euthanized 7 days after the beginning of irinotecan treatment, and small intestines were collecte

276 Although PDT potentiated irinotecan treatment, we also demonstrate that irinoteca

277 intestinal toxicity was observed relative to irinotecan treatment.

278 Irinotecan treats a range of solid tumors, but its effec

279 The topoisomerase I (TOP1) inhibitor irinotecan triggers cell death by trapping TOP1 on DNA,

280 ncer cells, treated with the anticancer drug Irinotecan under a series of time- and concentration-dep

281 umors in a phase II study of bevacizumab and irinotecan underwent brain MR and (18)F-FDG PET within 2

282 21 evaluated the activity of vincristine and irinotecan (VI) in patients with newly diagnosed diffuse

283 ol AHEP0731 and treated with vincristine and irinotecan (VI).

284 nts received oxaliplatin, 5-fluorouracil and irinotecan via chronomodulated schedules delivered by an

285 ts: Of the 696 PICCOLO trial patients in the irinotecan-vs-irinotecan with panitumumab randomization,

286 The starting dose of irinotecan was 700 mg in patients with the *1/*1 and *1/

287 y in combination with the DSB-inducing agent irinotecan was observed in a disease relevant model.

288 The time-dependent penetration of irinotecan was visualized and the localization of three

289 plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in prev

290 Oral T and intravenous (IV) irinotecan were administered on days 1 to 5 of 21-day cy

291 m and Tegafur/Gimeracil (TS-1)/Oxaliplatinum/Irinotecan were found to be effective.

292 inations of oxaliplatin, 5-fluorouracil, and irinotecan were investigated for metastatic colorectal c

293 ontaining fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide

294 s 23% (95% CI, 9% to 40%) for cetuximab plus irinotecan with a hazard ratio of 0.74 (95% CI, 0.42 to

295 Irinotecan with BBB disruption did not impede tumor grow

296 and subsequent fluorouracil, leucovorin, and irinotecan with or without bevacizumab in the second-lin

297 PICCOLO trial patients in the irinotecan-vs-irinotecan with panitumumab randomization, 331 had suffi

298 , median (IQR) PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (ir

299 range [IQR]) PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (ir

300 -970, enhanced the in vivo tumor response to irinotecan without additional toxicity.